NASDAQ:SNDX

Syndax Pharmaceuticals Stock Forecast, Price & News

$21.68
+1.08 (+5.24 %)
(As of 04/14/2021 12:00 AM ET)
Add
Compare
Today's Range
$20.25
Now: $21.68
$22.18
50-Day Range
$20.60
MA: $23.26
$25.18
52-Week Range
$10.13
Now: $21.68
$27.85
Volume735,404 shs
Average Volume670,195 shs
Market Capitalization$1.05 billion
P/E RatioN/A
Dividend YieldN/A
Beta1.8
Syndax Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, develops therapies for the treatment of cancer. The company's lead product candidates are entinostat that is in Phase III clinical trials for the treatment of advanced hormone receptor positive (HR+), human epidermal growth factor receptor 2 negative (HER2-) breast cancer; and SNDX-5613 in Phase I/II clinical trial inhibitor that targets the binding interaction of Menin with mixed lineage leukemia-rearranged and acute myeloid leukemia with a mutated nucleophosmin 1. It also develops entinostat with Keytruda (pembrolizumab) in a Phase Ib/II clinical trials for the treatment of non-small cell lung cancer and melanoma or microsatellite stable colorectal carcinoma; and with Tecentriq (atezolizumab) in Phase Ib/II clinical trials to treat patients with HR+ and HER2- metastatic breast cancer. In addition, the company develops SNDX-6352, a monoclonal antibody that blocks the colony stimulating factor 1 that is in Phase I/II clinical trial in patients with chronic graft versus host disease; and as a monotherapy and in combination with Imfinzi (durvalumab), which is completed Phase Ib dose trials for the treatment of solid tumors. Syndax Pharmaceuticals, Inc. has clinical collaborations with MSD International GmbH; Genentech, Inc.; and Merck KGaA and Pfizer. It also has collaborative research and development agreement with National Cancer Institute; clinical trial agreement with Eastern Cooperative Oncology Group; and license agreement with Kyowa Hakko Kirin Co., Ltd. The company was founded in 2005 and is headquartered in Waltham, Massachusetts.
Syndax Pharmaceuticals logo

Industry, Sector and Symbol

Industry Pharmaceutical preparations
Sub-IndustryN/A
SectorMedical
Current SymbolNASDAQ:SNDX
CUSIPN/A
Phone781-419-1400
Employees43
Year FoundedN/A

Debt

Price-To-Earnings

Sales & Book Value

Annual Sales$1.52 million
Book Value$1.16 per share

Profitability

Net Income$-56,050,000.00
Net Margins-4,656.63%

Miscellaneous

Market Cap$1.05 billion
Next Earnings Date5/6/2021 (Estimated)
OptionableOptionable

Headlines

Is SNDX Stock A Buy or Sell?
April 8, 2021 |  finance.yahoo.com
Syndax Pharmaceuticals (NASDAQ:SNDX) Shares Up 6.7%
April 1, 2021 |  americanbankingnews.com
Syndax: Q4 Earnings Snapshot
March 8, 2021 |  finance.yahoo.com
Syndax Pharmaceuticals: Q4 Earnings Insights
March 8, 2021 |  finance.yahoo.com
News for Syndax Pharmaceuticals Inc
November 30, 2020 |  markets.businessinsider.com
See More Headlines

MarketRank

Overall MarketRank

1.64 out of 5 stars

Medical Sector

340th out of 2,019 stocks

Pharmaceutical Preparations Industry

154th out of 772 stocks

Analyst Opinion: 3.4Community Rank: 2.5Dividend Strength: 0.0Insider Behavior: 1.7Valuation: 0.6 5 -4 -3 -2 -1 -
$21.68
+1.08 (+5.24 %)
(As of 04/14/2021 12:00 AM ET)
30 days | 90 days | 365 days | Advanced Chart

Receive SNDX News and Ratings via Email

Sign-up to receive the latest news and ratings for SNDX and its competitors with MarketBeat's FREE daily newsletter.

speech bubbles
speech bubbles











Syndax Pharmaceuticals (NASDAQ:SNDX) Frequently Asked Questions

Is Syndax Pharmaceuticals a buy right now?

11 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Syndax Pharmaceuticals in the last year. There are currently 2 hold ratings and 9 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "buy" Syndax Pharmaceuticals stock.
View analyst ratings for Syndax Pharmaceuticals
or view top-rated stocks.

What stocks does MarketBeat like better than Syndax Pharmaceuticals?

Wall Street analysts have given Syndax Pharmaceuticals a "Buy" rating, but there may be better short-term opportunities in the market. Some of MarketBeat's past winning trading ideas have resulted in 5-15% weekly gains. MarketBeat just released five new trading ideas, but Syndax Pharmaceuticals wasn't one of them. MarketBeat thinks these five stocks may be even better buys.
View MarketBeat's top stock picks here.

Are investors shorting Syndax Pharmaceuticals?

Syndax Pharmaceuticals saw a increase in short interest in the month of March. As of March 31st, there was short interest totaling 6,790,000 shares, an increase of 27.9% from the March 15th total of 5,310,000 shares. Based on an average daily trading volume, of 671,700 shares, the short-interest ratio is presently 10.1 days.
View Syndax Pharmaceuticals' Short Interest
.

When is Syndax Pharmaceuticals' next earnings date?

Syndax Pharmaceuticals is scheduled to release its next quarterly earnings announcement on Thursday, May 6th 2021.
View our earnings forecast for Syndax Pharmaceuticals
.

How were Syndax Pharmaceuticals' earnings last quarter?

Syndax Pharmaceuticals, Inc. (NASDAQ:SNDX) issued its quarterly earnings data on Sunday, March, 7th. The company reported ($0.44) earnings per share for the quarter, topping the consensus estimate of ($0.49) by $0.05. Syndax Pharmaceuticals had a negative trailing twelve-month return on equity of 77.47% and a negative net margin of 4,656.63%.
View Syndax Pharmaceuticals' earnings history
.

How has Syndax Pharmaceuticals' stock been impacted by Coronavirus (COVID-19)?

Syndax Pharmaceuticals' stock was trading at $11.79 on March 11th, 2020 when Coronavirus (COVID-19) reached pandemic status according to the World Health Organization. Since then, SNDX shares have increased by 83.9% and is now trading at $21.68.
View which stocks have been most impacted by COVID-19
.

What price target have analysts set for SNDX?

11 analysts have issued 12-month target prices for Syndax Pharmaceuticals' stock. Their forecasts range from $15.00 to $33.00. On average, they expect Syndax Pharmaceuticals' share price to reach $28.55 in the next twelve months. This suggests a possible upside of 31.7% from the stock's current price.
View analysts' price targets for Syndax Pharmaceuticals
or view top-rated stocks among Wall Street analysts.

Who are Syndax Pharmaceuticals' key executives?

Syndax Pharmaceuticals' management team includes the following people:
  • Dr. Briggs W. Morrison M.D., CEO & Director (Age 61, Pay $848.43k)
  • Mr. Michael A. Metzger, Pres, COO & Director (Age 50, Pay $795.35k)
  • Dr. Michael L. Meyers, Chief Medical Officer & Sr. VP (Age 70, Pay $599.3k)
  • Dr. Peter Ordentlich, Co-Founder & Chief Scientific Officer (Age 52)
  • Dr. Richard A. Heyman, Co-Founder (Age 64)
  • Dr. Ronald M. Evans Ph.D., Co-Founder, Advisor and Chair of Scientific Advisory Board
  • Dr. Michael Downes Ph.D., Co-Founder
  • Ms. Daphne Karydas M.B.A., Chief Financial Officer (Age 48)
  • Mr. Luke J. Albrecht, Sr. VP, Gen. Counsel & Sec. (Age 42)
  • Dr. Edward A. Sausville M.D., Ph.D., Advisor

Who are some of Syndax Pharmaceuticals' key competitors?

What other stocks do shareholders of Syndax Pharmaceuticals own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Syndax Pharmaceuticals investors own include OPKO Health (OPK), Exelixis (EXEL), Verastem (VSTM), Inovio Pharmaceuticals (INO), SCYNEXIS (SCYX), Sorrento Therapeutics (SRNE), VBI Vaccines (VBIV), Idera Pharmaceuticals (IDRA), TherapeuticsMD (TXMD) and Micron Technology (MU).

When did Syndax Pharmaceuticals IPO?

(SNDX) raised $66 million in an IPO on Thursday, March 3rd 2016. The company issued 4,400,000 shares at $14.00-$16.00 per share. Morgan Stanley and Citigroup served as the underwriters for the IPO and JMP Securities and Oppenheimer & Co. were co-managers.

What is Syndax Pharmaceuticals' stock symbol?

Syndax Pharmaceuticals trades on the NASDAQ under the ticker symbol "SNDX."

Who are Syndax Pharmaceuticals' major shareholders?

Syndax Pharmaceuticals' stock is owned by a number of retail and institutional investors. Top institutional shareholders include Pacer Advisors Inc. (0.01%). Company insiders that own Syndax Pharmaceuticals stock include Briggs Morrison, Michael A Metzger and Peter Ordentlich.
View institutional ownership trends for Syndax Pharmaceuticals
.

Which institutional investors are buying Syndax Pharmaceuticals stock?

SNDX stock was acquired by a variety of institutional investors in the last quarter, including Pacer Advisors Inc..
View insider buying and selling activity for Syndax Pharmaceuticals
or or view top insider-buying stocks.

How do I buy shares of Syndax Pharmaceuticals?

Shares of SNDX can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Syndax Pharmaceuticals' stock price today?

One share of SNDX stock can currently be purchased for approximately $21.68.

How much money does Syndax Pharmaceuticals make?

Syndax Pharmaceuticals has a market capitalization of $1.05 billion and generates $1.52 million in revenue each year. The company earns $-56,050,000.00 in net income (profit) each year or ($1.84) on an earnings per share basis.

How many employees does Syndax Pharmaceuticals have?

Syndax Pharmaceuticals employs 43 workers across the globe.

What is Syndax Pharmaceuticals' official website?

The official website for Syndax Pharmaceuticals is www.syndax.com.

Where are Syndax Pharmaceuticals' headquarters?

Syndax Pharmaceuticals is headquartered at 35 GATEHOUSE DRIVE BUILDING D FLOOR 3, WALTHAM MA, 02451.

How can I contact Syndax Pharmaceuticals?

Syndax Pharmaceuticals' mailing address is 35 GATEHOUSE DRIVE BUILDING D FLOOR 3, WALTHAM MA, 02451. The company can be reached via phone at 781-419-1400 or via email at [email protected]


This page was last updated on 4/15/2021 by MarketBeat.com Staff
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more.

MarketBeat is accredited by the Better Business Bureau

© American Consumer News, LLC dba MarketBeat® 2010-2021. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security. Learn more.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information

© 2021 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer. Fundamental company data provided by Zacks Investment Research. As a bonus to opt-ing into our email newsletters, you will also get a free subscription to the Liberty Through Wealth e-newsletter. You can opt out at any time.